Menu

Blog

Feb 20, 2021

The NIA Is Funding Clinical Trials Against Aging

Posted by in categories: biotech/medical, life extension

Companies that are creating rejuvenation biotechnology interventions must develop their products to target individual diseases in order to be approved by the FDA. While that is still the case, this particular FOA is intended to promote broader research that does not necessarily target individual diseases as endpoints.


The National Institutes of Aging in the United States, a component of the National Institutes of Health, is funding clinical trials for interventions that directly affect the root causes of age-related diseases.

Direct funding for trials against aging

Probably the most important and interesting part of this Funding Opportunity Announcement (FOA) is that the NIA specifically mentions “multiple chronic conditions” caused by the processes of aging along with more conventional trials that are targeted directly at specific downstream effects of aging.

Leave a reply